Followers | 897 |
Posts | 149197 |
Boards Moderated | 0 |
Alias Born | 08/13/2010 |
Thursday, October 18, 2018 2:04:27 PM
Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.
Recent ABBV News
- AbbVie et SpinUp encouragent l'innovation dans le secteur des sciences de la vie au Canada avec le lancement du Prix AbbVie des innovateurs en biotechnologies • PR Newswire (Canada) • 09/26/2024 12:00:00 PM
- AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease • PR Newswire (US) • 09/26/2024 12:00:00 PM
- AbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award • PR Newswire (Canada) • 09/26/2024 12:00:00 PM
- New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement • PR Newswire (US) • 09/25/2024 11:00:00 AM
- Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns • PR Newswire (US) • 09/24/2024 12:00:00 PM
- AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer • PR Newswire (US) • 09/20/2024 11:32:00 AM
- Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China • PR Newswire (US) • 09/11/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 07:30:45 PM
- AbbVie reçoit l'approbation de Santé Canada pour l'emploi de CONSTELLA® (linaclotide) dans le traitement de la constipation fonctionnelle chez les enfants âgés de 6 à 17 ans • PR Newswire (Canada) • 09/10/2024 11:00:00 AM
- Health Canada Approves AbbVie's CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age • PR Newswire (Canada) • 09/10/2024 11:00:00 AM
- AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs • PR Newswire (US) • 09/09/2024 01:00:00 PM
- AbbVie Declares Quarterly Dividend • PR Newswire (US) • 09/06/2024 02:13:00 PM
- AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia • PR Newswire (Canada) • 09/04/2024 12:00:00 PM
- AbbVie reçoit une recommandation favorable de la part de l'Agence des médicaments du Canada pour le remboursement de VRAYLAR® (cariprazine) dans le traitement de la schizophrénie • PR Newswire (Canada) • 09/04/2024 12:00:00 PM
- AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases • PR Newswire (US) • 08/27/2024 12:15:00 PM
- SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator • PR Newswire (US) • 08/27/2024 12:05:00 PM
- European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma • PR Newswire (US) • 08/19/2024 06:05:00 PM
- AbbVie annonce les premiers remboursements provinciaux, en Ontario et au Québec, d'EPKINLY(MC) (epcoritamab) administré par voie sous-cutanée pour le traitement du lymphome diffus à grandes cellules B en vertu d'un nouveau processus d'accès rapide • PR Newswire (Canada) • 08/15/2024 01:14:00 PM
- AbbVie Announces Ontario and Quebec are First Provinces to Reimburse Subcutaneous EPKINLY™ (epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process • PR Newswire (Canada) • 08/15/2024 01:13:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2024 08:09:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/08/2024 09:40:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/07/2024 08:22:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 07:00:51 PM
- AbbVie Completes Acquisition of Cerevel Therapeutics • PR Newswire (US) • 08/01/2024 12:23:00 PM
- Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day • PR Newswire (US) • 07/30/2024 12:00:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM